The Lancet Commission on Skin Health: a roadmap to integrating skin care into global public health

Table of Contents

1. Key Highlights
2. Introduction
3. Why skin health matters: burden, disability and social consequences
4. Where health systems fall short: access, funding and workforce gaps
5. Aligning skin health with WHO priorities: UHC, primary care and neglected tropical diseases
6. Practical pathways: task-shifting, teledermatology and education
7. Research, data and funding: closing the mismatch between burden and investment
8. Policy levers: essential medicines, guidelines and workforce strategies
9. Case studies: translating policy into practice
10. Equity and stigma: addressing social determinants and mental health
11. Implementation challenges and trade-offs
12. Measuring success: indicators and accountability
13. From global guidance to national action: steps for policymakers
14. The role of professional societies and civil society
15. Innovation frontiers: diagnostics, therapeutics and digital tools
16. Ethical considerations and equity safeguards
17. Next steps for the international community
18. FAQ

Key Highlights

• The Lancet Commission on Skin Health sets out a strategic agenda to bring skin disease prevention, diagnosis and treatment into alignment with WHO priorities—especially universal health coverage, primary care strengthening, and neglected tropical disease control.
• Addressing skin health requires coordinated policy action: improved surveillance and data, workforce development including task-shifting and telemedicine, essential medicines and diagnostics, and targeted funding that reflects disease burden and disability.

Introduction

Skin conditions are among the most common health problems worldwide, yet they receive disproportionately little attention in global health planning and financing. The Lancet Commission on Skin Health reframes skin disease as a public health priority by mapping out concrete steps to align dermatological care with the World Health Organization’s policy goals. The Commission argues that better skin health contributes to universal health coverage, reduces avoidable disability, and advances equity—particularly where neglected tropical diseases and stigmatizing skin conditions exacerbate poverty and social exclusion.

This article examines the Commission’s core recommendations, explains how they correspond to WHO priorities, and outlines practical pathways for countries, health systems, and funders to translate vision into impact. The analysis synthesizes Commission themes with evidence from global burden studies, existing programs in low- and middle-income settings, and innovations in training and service delivery that can be scaled rapidly. The aim is to provide clinicians, policymakers and civil society with an actionable synthesis that moves skin health from a marginal concern to an integrated component of public health strategy.

Why skin health matters: burden, disability and social consequences

Skin conditions generate more years lived with disability (YLDs) than many better-known diseases. They range from acute infectious presentations—scabies, impetigo, yaws, and fungal infections—to chronic inflammatory disorders such as eczema, psoriasis and hidradenitis suppurativa, and to life-threatening malignancies including melanoma and non-melanoma skin cancers. Beyond clinical morbidity, skin disease carries social and economic consequences: visible lesions invite stigma, reduce educational and employment opportunities, and worsen mental health.

Global burden studies repeatedly identify skin disorders as a leading cause of non-fatal health loss. That position matters for health systems because YLDs represent chronic care needs and lost productivity. Consider at-scale conditions such as atopic dermatitis: children with uncontrolled disease miss school and caregivers lose workdays; untreated fungal infections propagate within households and communities; scabies outbreaks—especially in crowded settings—can lead to bacterial complications that require systemic care. Neglect compounds consequences: delayed diagnosis of skin cancer reduces survival; untreated leprosy causes disability and social exclusion.

The Commission emphasizes that measuring burden only by mortality ignores the persistent, cumulative harms of skin conditions. Disability-adjusted frameworks capture the long tail of suffering that skin disease imposes, but policy attention, research funding, and essential-service packages often lag behind those metrics. Reconciling that mismatch underpins much of the Commission’s agenda.

Where health systems fall short: access, funding and workforce gaps

Health systems under-invest in dermatological services for three interrelated reasons: perceived low priority, scarcity of trained personnel, and limited availability of diagnostics and therapies at lower tiers of care.

Perception and priority. Policymakers prioritize interventions tied to mortality reduction and epidemic control. Visible but non-fatal conditions are often considered cosmetic or individual rather than public health problems. That perception influences budgeting, leading to exclusion from basic benefits packages and medicines lists.

Workforce shortages. Dermatologists are concentrated in urban centers and high-income countries. Many low- and middle-income countries (LMICs) lack dermatologists entirely or have a handful serving millions. Primary care clinicians often receive minimal dermatology training during medical education, and community health workers rarely have standardized protocols for common skin complaints. The result: delayed diagnosis, over-referral to scarce specialists, and inconsistent treatment.

Supply chain and essential medicines. Effective management of many skin conditions requires access to simple, affordable medicines—topical corticosteroids, antifungals, antiparasitics, antibiotics for secondary infection—and to point-of-care diagnostics such as dermatoscopes or basic laboratory tests. These are often unavailable in rural clinics. In the case of skin neglected tropical diseases (NTDs) like yaws or scabies, mass drug administration programs exist but face logistic and funding constraints that leave many affected communities untreated.

Funding misalignment. Research investment and development assistance for dermatology do not mirror disease burden. Studies have documented disparities between NIH funding for skin research and the global burden of skin disease. Philanthropic and bilateral funding streams tend to favor high-profile infectious threats and vertical programs, limiting innovation in routine skin care delivery.

These gaps are not insoluble. The Commission outlines ways to reorganize care, train non-specialist providers, and ensure essential commodities reach primary care settings—moves that complement broader WHO priorities such as strengthening primary health care and achieving universal health coverage.

Aligning skin health with WHO priorities: UHC, primary care and neglected tropical diseases

The World Health Organization’s framework for health systems emphasizes universal health coverage (UHC), integrated people-centered services, and the control and elimination of neglected diseases. Skin health intersects with each of these priorities in concrete ways.

Universal Health Coverage. UHC aims to ensure that all people receive the health services they need without financial hardship. Inclusion of skin services in essential benefit packages is a necessary step to meet UHC goals. That means defining a basic set of dermatological interventions that are cost-effective, clinically appropriate, and feasible at primary care level: case management for scabies and impetigo; topical therapies for common inflammatory dermatoses; early detection and referral pathways for skin cancers; and mental health support for disfiguring conditions.

Primary health care strengthening. Primary care is the most efficient setting to manage common skin problems. Integrating dermatology into primary services reduces unnecessary specialist referrals and shortens time to treatment. Achieving this requires curricula reform for medical, nursing and community health worker training; standardised clinical guidelines; and decision-support tools that fit typical primary care workflows.

Neglected tropical diseases. Several NTDs present primarily with skin manifestations. WHO’s NTD roadmaps now emphasize integrated approaches for skin NTDs—combining active case finding, community engagement and mass drug administration where indicated. The Commission advocates for leveraging NTD platforms to expand access to skin care more broadly: programs that detect and treat leprosy or yaws can also screen for common dermatoses and coordinate referrals.

Aligning dermatology with WHO priorities yields mutual benefits. Investing in skin health advances UHC by addressing a high-burden, high-disability group of conditions. Strengthening primary care to manage skin disease builds system resilience and improves patient flow for other conditions. And embedding skin health in NTD programming increases the value of existing investments by widening their public health impact.

Practical pathways: task-shifting, teledermatology and education

Translating policy into better outcomes requires practical delivery models that address workforce and access constraints. The Commission highlights several approaches that have already demonstrated feasibility.

Task-shifting and task-sharing. Training non-specialists—primary care doctors, nurses, mid-level clinicians, and community health workers—to manage common skin conditions is cost-effective and scalable. Protocolized care pathways enable safe treatment by non-specialists. For example, a nurse trained to diagnose and treat scabies using standardized algorithms can manage community outbreaks without overburdening scarce dermatologists. Supervision and referral protocols maintain quality.

Teledermatology and digital decision support. Dermatology is visually oriented, making it amenable to remote triage and consultation. Store-and-forward teledermatology systems, real-time video consultations and AI-assisted diagnostic tools can expand access in underserved areas. Practical implementations range from simple photo-based teleconsults linking rural clinics to urban dermatologists, to integrated platforms that combine image transmission with electronic medical records and referral tracking.

Clinical education reforms. Embedding dermatology into undergraduate and postgraduate curricula increases frontline competence. Short, high-yield modules focused on recognition of common infections, inflammatory disorders and skin manifestations of systemic disease can transform primary care readiness. Simulation training, case-based learning and mentorship models accelerate skill transfer.

Supply chain innovations. Ensuring availability of topical therapies and essential systemic agents at primary care facilities calls for procurement reforms and prioritization of essential medicines lists. Pooled procurement mechanisms, subsidized formularies, and integration of skin medicines into existing logistics systems (e.g., those used for NTD drugs or maternal-child health supplies) lower costs and improve access.

Community engagement and self-care. Many skin conditions respond to public education and improved hygiene. Community health education on wound care, hygiene, and early signs of disease reduces stigma and promotes timely care-seeking. For chronic inflammatory conditions, patient education on topical application, adherence and trigger avoidance improves outcomes.

These pathways are not mutually exclusive. Integrated programs that combine training, telemedicine links, essential medicine access and community engagement produce multiplier effects—faster diagnosis, fewer complications, and lower system costs.

Research, data and funding: closing the mismatch between burden and investment

A persistent theme in the Commission is the discrepancy between the global burden of skin disease and the volume of research and funding allocated to it. Addressing that gap requires coordinated efforts across research funders, national governments and philanthropic organizations.

Improved surveillance and data systems. Routine health information systems rarely capture skin disease burden accurately. Integrating dermatology indicators into national health surveys, electronic medical records, and sentinel surveillance programs fills that gap. Standardized case definitions, severity grading and disability measures enable cross-country comparisons and evidence-based policy.

Targeted research priorities. Research should prioritize implementation science—how to deliver proven interventions at scale—along with epidemiology, health systems research, and studies on mental health impacts of skin disease. There is also a role for translational research on diagnostics, affordable topical formulations and repurposing of existing antimicrobials for skin NTDs.

Bridging funding divides. National health budgets must include dermatology within essential health service packages. International funders and donors should recognize the cost-effectiveness of primary-care based skin interventions and channel resources into capacity building, supply chains and programmatic research. Philanthropic investments can seed pilot programs that, if successful, attract government scale-up.

Examples from other disease areas illustrate how funding realignment produces rapid gains. HIV programs that integrated primary care and community outreach improved access to a range of services beyond antiretroviral therapy. Similar integration for skin health—anchored in primary care—can leverage existing delivery platforms rather than creating parallel systems.

Policy levers: essential medicines, guidelines and workforce strategies

Policy frameworks set the conditions for sustained change. The Commission identifies several levers that national governments and global agencies can use immediately.

Update essential medicines lists. National essential medicines lists should include key dermatological agents for common infections, inflammation and NTDs. Inclusion facilitates procurement, subsidization and consistent availability at primary care level.

Develop and adopt clinical guidelines. Simple, evidence-based guidelines for primary-care management of common skin conditions reduce practice variation. Algorithmic care pathways for scabies, tinea infections, eczema and common ulcerative lesions allow safe treatment by non-specialists and streamline referral thresholds.

Workforce planning and incentives. Health workforce policies should include dermatology competencies for multiple cadres and incentives to retain trained providers in rural settings. Task-shifting policies must be accompanied by legal and supervisory frameworks to preserve quality and patient safety.

Integrate skin health into NTD strategies and UHC roadmaps. National NTD plans already engage communities and conduct active case finding for skin conditions. Embedding dermatology into broader UHC roadmaps ensures that funding, monitoring and accountability mechanisms support sustainable service delivery.

Regulatory and procurement reforms. Streamlining regulatory pathways for essential topical agents and enabling pooled procurement across regions reduce costs. Public–private partnerships may improve supply chains, particularly for low-cost generic formulations.

These policy measures require political will and cross-sector collaboration—between ministries of health, finance, education and social services—to translate technical recommendations into budget lines and implementation plans.

Case studies: translating policy into practice

Drawing lessons from real-world programs demonstrates how the Commission’s recommendations can operate at scale.

Case: integrated scabies control in Pacific island settings. Several Pacific nations have used mass drug administration with oral ivermectin, combined with community engagement and improvements in hygiene, to suppress scabies prevalence. Program success depended on clear community communication, coordination with primary care clinics for case management and monitoring for adverse events. Scabies control reduced secondary bacterial infections and decreased clinic visits for skin complaints.

Case: teledermatology networks in large LMIC health systems. Teleconsultation programs in South and Southeast Asia connect rural clinics with urban dermatologists, enabling remote triage and management for common conditions. These networks reduce wait times for specialist input, decrease unnecessary referrals, and provide on-the-job learning for primary care clinicians.

Case: task-shifting for leprosy detection in South Asia and Africa. Community health workers trained to detect early signs of leprosy and refer promptly have contributed to timely diagnosis and treatment, preventing disability. Program models include community screening campaigns integrated into other outreach activities, such as immunization drives or maternal-child health visits.

Each case shares common enablers: clear protocols, supervision and quality assurance, community trust, and reliable supply of medicines or diagnostics. They also expose challenges—sustaining funding after pilot phases, maintaining trained staff in remote areas, and integrating data into national information systems.

Equity and stigma: addressing social determinants and mental health

Skin disease disproportionately affects marginalized populations: those living in poverty, in overcrowded housing, or without access to basic water and sanitation. The visible nature of many skin conditions amplifies social stigma, which in turn discourages individuals from seeking care and perpetuates cycles of exclusion.

Program design must integrate social determinants. Interventions that combine medical treatment with improvements in water, sanitation and hygiene (WASH) have greater impact than medical treatment alone for conditions linked to environmental risk. School-based programs—screening, education and treatment—target children who are particularly vulnerable to scabies, tinea and impetigo, and mitigate transmission within households.

Mental health integration. Long-standing, disfiguring skin disease correlates with anxiety, depression and social withdrawal. Embedding mental health screening and counseling into dermatology services improves overall outcomes. Psychosocial support groups, peer counseling and community-based rehabilitation services reduce isolation and improve adherence to treatment.

Gender and age considerations. Certain skin conditions have gendered patterns of care-seeking and social impact. For example, adolescents with acne may experience significant self-esteem issues that affect educational attainment. Elderly populations face increased risk of skin cancers and chronic wounds that require specialized management. Equity-oriented programs tailor approaches to these demographic realities.

Addressing stigma also requires public communication campaigns that normalize skin conditions as treatable health issues rather than moral or social failings. Civil society organizations and patient advocacy groups play a central role in reframing public narratives and pressing for policy changes.

Implementation challenges and trade-offs

Even well-designed strategies face obstacles. The Commission anticipates and addresses several trade-offs that policymakers will encounter.

Resource constraints. In low-resource settings, prioritizing which services to include in basic health packages involves trade-offs. Policymakers must weigh immediate cost against long-term disability reduction. Cost-effectiveness analyses help identify high-value interventions—such as scabies control in high-prevalence communities or early melanoma detection in high-risk populations.

Maintaining quality with task-shifting. Expanding service delivery through non-specialist providers raises concerns about diagnostic accuracy and appropriate use of medicines, particularly antibiotics and corticosteroids. Strong supervisory systems, simple treatment algorithms and quality audits mitigate these risks.

Antimicrobial resistance (AMR) concerns. Management of infected skin lesions often involves antibiotics. Programs must prioritize appropriate stewardship, including diagnostic confirmation of bacterial infection when possible, use of narrow-spectrum agents, and adherence to treatment guidelines to limit AMR risk.

Sustainability after pilot funding ends. Many promising initiatives begin as donor-funded pilots. Transitioning to domestic financing requires early alignment with national priorities and demonstration of cost-effectiveness. Embedding programs into existing health system budgets and leveraging cross-program synergies improve sustainability prospects.

Data limitations. Weak surveillance reduces the ability to measure impact and advocate for sustained investment. Investing in routine monitoring from the start allows programs to demonstrate outcomes and adapt strategies based on evidence.

Recognizing these challenges does not justify inaction. Instead, they underscore the need for pragmatic piloting, rigorous monitoring, and flexible policies that adapt to local contexts.

Measuring success: indicators and accountability

To ensure progress, stakeholders must define clear indicators and accountability mechanisms. The Commission recommends a combination of input, process and outcome metrics.

Input indicators. Availability of essential dermatological medicines at primary care clinics, number of trained non-specialist providers, and inclusion of skin services in national benefits packages.

Process indicators. Proportion of primary care facilities using standardized skin care guidelines, number of teledermatology consultations per 10,000 population, and frequency of community outreach or school screening activities.

Outcome indicators. Reductions in prevalence of common infections (scabies, impetigo), decreases in disability-adjusted metrics for chronic inflammatory skin diseases, time to diagnosis for skin cancers, and measures of patient-reported outcomes such as quality of life and stigma scores.

Equity indicators. Disaggregation of outcomes by geography, socioeconomic status, gender and age ensures that interventions reach the most vulnerable.

Accountability frameworks. Regular reporting to national health authorities and integration into UHC monitoring platforms creates incentives for sustained action. International partners can support capacity building for data collection and analysis. Civil society and patient groups provide important checks by monitoring service quality and advocating for underserved populations.

Measuring economic impact also builds the investment case. Analyses that quantify productivity gains from reduced morbidity or cost-savings from fewer specialist referrals bolster arguments to finance skin health within constrained budgets.

From global guidance to national action: steps for policymakers

For ministries of health and national planners, the path from Commission recommendations to implementation involves a sequence of pragmatic steps.

1. Situational analysis. Map the burden and service gaps using existing health data, facility assessments and stakeholder consultations. Identify high-burden regions and priority conditions.
2. Define essential package elements. Determine which dermatological interventions are feasible at primary care level and should be included in the national UHC benefits package.
3. Workforce strategy. Update pre-service education and develop short-course in-service training for primary care cadres. Establish supervision, referral and continuing medical education mechanisms.
4. Supply chain and financing. Ensure inclusion of core dermatology medicines in procurement plans and explore pooled purchasing or donor co-financing where necessary.
5. Pilot integrated delivery models. Test task-shifting, teledermatology and community engagement models in diverse settings. Use implementation research to refine approaches.
6. Monitoring and scale-up. Build indicators into national health information systems and plan gradual expansion with cross-sector support for sustainability.
7. Public engagement. Launch communication campaigns to reduce stigma, encourage care seeking and mobilize community support.

This sequence aligns technical work with political and financial realities. Early wins—such as demonstrable reductions in scabies prevalence in pilot districts—create momentum for broader adoption.

The role of professional societies and civil society

Dermatology professional societies, patient advocacy groups and non-governmental organizations play multiple roles: developing guidelines, running training programs, advocating for policy change, and supporting service delivery. Partnerships between professional societies in high-income countries and counterparts in LMICs can accelerate capacity building through twinning arrangements, mentorship, and remote education.

Civil society ensures that programs remain patient-centered. People with lived experience of disfiguring skin disease provide essential perspectives on stigma, access barriers and acceptability of interventions. Donor agencies and governments should incorporate patient voices into program design and evaluation.

Private sector engagement also has potential value, particularly for supply chains and digital health solutions. Clear regulatory frameworks and public–private partnership models protect public interest while leveraging innovation and efficiency from private actors.

Innovation frontiers: diagnostics, therapeutics and digital tools

The Commission identifies areas where targeted innovation could transform care.

Point-of-care diagnostics. Rapid, field-friendly tests for bacterial infection, fungal pathogens, or biomarkers of inflammatory disease would reduce inappropriate antibiotic use and speed targeted therapy.

Affordable topical formulations. Reformulation of existing agents into stable, low-cost topical products suitable for tropical climates improves adherence and reach. Development of fixed-dose combinations for common co-infections could simplify treatment regimens.

Digital diagnostics and AI. Machine-learning algorithms trained on diverse skin images can assist frontline providers in triage and diagnosis. Careful validation in different skin types and contexts is essential to avoid bias and ensure safe deployment.

Integrated digital platforms. Systems that combine teleconsultation, decision support, supply chain tracking and routine data collection reduce fragmentation and strengthen continuity of care.

These innovations require cross-disciplinary collaboration and funding models that de-risk early-stage development while ensuring equitable access, particularly in low-resource settings.

Ethical considerations and equity safeguards

Scaling dermatology services raises ethical questions that programs must address proactively.

Data privacy. Teledermatology and digital imaging involve sensitive visual information. Programs must adopt robust consent processes, secure data storage and policies that prevent misuse.

Equity in AI. Training datasets must include diverse skin tones and global populations to avoid biased algorithms that underperform in underrepresented groups.

Access and affordability. Innovations and new therapies should be deployed with affordability measures to avoid widening inequities between urban and rural, or high- and low-income populations.

Community consent and cultural sensitivity. Community engagement must respect local norms and beliefs about skin disease, integrating traditional healers where appropriate to increase acceptability.

Transparency in program evaluation and funding supports public trust and long-term sustainability.

Next steps for the international community

The Lancet Commission outlines a collaborative agenda that requires global partners to act in concert.

WHO leadership. WHO can integrate skin health indicators into global monitoring frameworks and provide technical guidance for national implementation. Aligning skin health with NTD strategies and UHC roadmaps strengthens coherence.

Donor alignment. Donors should incorporate skin health into health system strengthening portfolios, funding training, supply chain improvements and implementation research.

Research funders. Agencies should prioritize implementation science and operational research in dermatology, alongside support for innovations in diagnostics and therapeutics.

Regional collaboration. Neighboring countries can pool procurement, share training curricula and coordinate cross-border surveillance for skin NTDs.

Philanthropy and private sector. Targeted philanthropic funding can catalyze pilots and innovations, while private sector partners can help scale digital platforms and supply chains under equitable terms.

The collective aim is to move skin health from peripheral concern to integrated component of global health programming—delivering measurable health gains, reducing disability, and improving lives.

FAQ

Q: Why prioritize skin health when other conditions cause higher mortality? A: Skin disease causes substantial non-fatal disability that impairs daily functioning, education and economic productivity. Many skin conditions are preventable or treatable with low-cost interventions delivered in primary care. Addressing skin health contributes to UHC and reduces long-term disability, which complements mortality-focused priorities.

Q: What are the most impactful interventions to start with? A: High-impact, feasible interventions include community-level scabies control in high-prevalence areas (including mass drug administration where indicated), training primary care providers in diagnosis and management of common dermatoses, ensuring availability of essential topical and systemic medicines, and integrating teledermatology for specialist support.

Q: How can countries with few dermatologists scale services safely? A: Task-shifting, combined with clear clinical algorithms, supervision by regional specialists, and telemedicine support, allows non-specialists to manage most common skin conditions safely. Training and routine quality assurance mechanisms are essential to maintain standards.

Q: Are there risks of increasing antimicrobial resistance by expanding treatment for skin infections? A: Appropriate stewardship must accompany expanded access. Protocols should emphasize correct diagnostics, use of narrow-spectrum antibiotics when indicated, and treatment duration guidance. Integrating stewardship into training and monitoring helps mitigate AMR risks.

Q: How can digital tools be deployed equitably? A: Ensure tools are validated across diverse skin tones and contexts, protect patient privacy, and design platforms that function with low bandwidth and on basic smartphones. Complement digital tools with in-person capacity building to avoid exclusive reliance on technology.

Q: What role do schools and community programs play? A: Schools are effective platforms for screening, health education and treatment of common infections among children. Community programs increase awareness, reduce stigma, and promote early care-seeking. Integrating skin health activities into existing outreach maximizes reach and cost-effectiveness.

Q: How should countries measure progress? A: Use a mix of input (availability of medicines, trained staff), process (use of guidelines, teleconsultations), outcome (prevalence reductions, time to diagnosis), and equity indicators. Include patient-reported outcomes and disaggregated data to monitor who benefits.

Q: Where can clinicians find training resources? A: National medical education authorities and professional dermatology societies often provide curricula and continuing education modules. International partnerships and tele-mentoring programs offer remote learning opportunities for clinicians in resource-limited settings.

Q: How to ensure sustainability after initial funding? A: Integrate programs into national health plans and budgets, demonstrate cost-effectiveness, and leverage cross-program synergies (e.g., NTD platforms, primary care strengthening) to embed services sustainably.

Q: How does addressing skin health advance broader health system goals? A: Strengthening primary care for skin conditions builds diagnostic and treatment capacity that applies to other conditions, improves linkage between community and facility care, and supports UHC through inclusion of high-burden, high-disability services in essential benefit packages.